Glympse Bio
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Glympse Bio was a Cambridge, Massachusetts-based biotechnology company founded in 2015 as a spinout of Dr. Sangeeta Bhatia's lab at MIT. It developed activity-based biosensors: injectable nanoparticles designed to interact with specific proteins linked to diseases, which are then collected and analyzed, enabling non-invasive, real-time monitoring of disease progression. Its primary target was nonalcoholic steatohepatitis (NASH), and it signed a strategic collaboration with Gilead Sciences in October 2019. It also advanced oncology and infectious disease programs, and raised about $93 million in venture funding.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Glympse Bio was founded in 2015 as a spinout of Dr. Sangeeta Bhatia's lab at MIT, based in Cambridge, Massachusetts.
- Gilead collaboration
In October 2019 Glympse announced a strategic collaboration with Gilead Sciences to evaluate its technology as a diagnostic and prognostic tool for NASH.
- Series B
Glympse raised $46.7 million in Series B financing led by Section 32 to support NASH pivotal studies and its oncology program.
- Merged with Sunbird Bio
Glympse Bio completed a merger with Sunbird Bio; the combined company operates as Sunbird Bio, with terms undisclosed.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.